Copyright
©The Author(s) 2015.
World J Gastrointest Oncol. Nov 15, 2015; 7(11): 317-327
Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.317
Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.317
Table 2 MET mRNA expressions and clinical outcomes in gastric cancer
n | Overexpression | Relation to clinicopathological factors | Relation to survival | Ref. | ||
Cut-off value | % | |||||
Tumor | 100 | Value determined by nonparametric receiver operating characteristics | 11 | M | Worse | [34] |
100 | ND | 24 | ND | ND | [43] | |
45 | N, stage, differentiated type | ND | [35] | |||
43 | Value of mean + 2 SD in noncancerous tissue | 70 | NA | ND | [36] | |
15 | Intestinal type | ND | [22] | |||
Serum | 52 | Detected | 62 | T, N, M, stage, recurrence, v | Worse | [37] |
- Citation: Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 2015; 7(11): 317-327
- URL: https://www.wjgnet.com/1948-5204/full/v7/i11/317.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v7.i11.317